항암화학요법-항구토제

소개글

항암화학요법-항구토제에 대한 보고서 자료입니다.

목차

없음

본문내용

stine > 300mg/㎡
Arsenic trioxide
Azacitidine
Bendamustine
Busulfan
Carboplatin
Carmustine ≤ 250mg/㎡
Cisplatin < 50mg/㎡
Clofarabine
Cyclophosphamide ≤ 1,500 mg/㎡
Cytarabine > 200mg/㎡
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Ifosfamide
Interferon alfa ≥ 10 million IU/m2
Irinotecan
Melphalan
Methotrexate 250 → 1,000 mg/㎡
Oxaliplatin
Temozolomide
저위험군
(10-30%)
Low emetic risk
(10-30 % frequency of emesis)
Amifostine ≤ 300 mg
Aldesleukin(IL-2) ≤ 12million units/㎡
Cytarabine (low dose) 100-200mg/㎡
Docetaxel
Doxorubicin (liposomal)
Etoposide
5-fluorouracil
Floxuridine
Gemcitabine
Interferon alfa > 5 < 10million IU/m2
Ixabepilone
Methotrexate > 50mg/㎡ < 250mg/㎡
Mitomycin
Mitoxantrone
Paclitaxel
paclitaxel-albumin
Pemetrexed
Pentostatin
Romidepsin
Topotecan
최소위험군
(10% 미만)
Minimal emetic risk
(< 10 % frequency of emesis)
Alemtuzumab
Asparaginase
Bevacizumab
Bleomycin
Bortezomib
Cetuximab
Cladribine
Cytarabine 〈 100 mg/㎡
Decitabine
Dexrazoxane
Denileukin diftitox
Fludarabine
Gemtuzumab ozogamicin
Interferon Alpha ≤ 5 million IU/m2
Methotrexate ≤ 50mg/㎡
Nelarabine
Panitumumab
Pegaspargase
Rituximab
Temsirolimus
Trastuzumab
Valrubicin
Vinblastine
Vincristine
Vinorelbine

키워드

항암화학요법 - 항구토제 일반원칙,   항구토제 일반원칙 및 요양급여기준,   항구토제 요양급여기준